Skip to main content

Table 3 Clinical predictors and metabolic parameters of Cox regression analysis for predicting PFS and OS

From: Baseline 18F-FDG PET/CT radiomics for prognosis prediction in diffuse large B cell lymphoma

Category

End points

Variables

Univariate analysis

Multivariate analysis

HR

95%CI

P

HR

95%CI

P

Clinical predictors

PFS

NCCN-IPI

1.331

1.145–1.548

 < 0.001

1.215

1.021–1.445

0.028

  

β2-MG

2.668

1.606–4.433

 < 0.001

1.904

1.060–3.421

0.031

 

OS

NCCN-IPI

1.419

1.174–1.715

 < 0.001

1.294

1.041–1.607

0.020

  

β2-MG

3.015

1.589–5.719

 < 0.001

1.933

0.927–4.030

0.079

Metabolic parameters

PFS

SUVmax

1.352

0.814–2.247

0.244

–

–

–

  

SDmax

5.592

2.652–11.790

 < 0.001

4.758

2.236–10.120

 < 0.001

  

TMTV

2.816

1.654–4.796

 < 0.001

2.186

1.275–3.750

0.004

 

OS

SUVmax

1.664

0.849–3.262

0.138

–

–

–

  

SDmax

4.499

2.126–9.517

 < 0.001

3.939

1.832–8.469

 < 0.001

  

TMTV

2.441

1.209–4.932

0.013

1.797

0.874–3.697

0.111

  1. PFS progression-free survival, OS overall survival, NCCN-IPI National Comprehensive Cancer Network-International Prognostic Index, β2-MG β2-microglobulin, SUVmax maximum standardized uptake value, Dmax the largest distance between two lesions, SDmax standardized Dmax, TMTV total metabolic tumor volume, HR hazard ratio, CI confidence interval.